Boston BioLife (www.bostonbiolife.com) is a cutting-edge organization that provides workshops for physicians and scientists interested in learning regenerative medicine. Its mission is to facilitate the introduction of emerging life sciences technologies to scientists and healthcare providers. [Read more…]
Hematopoietic Stem Cells (HSCs)
CDI Launches Opsis, Provia Expands Perinatal Storage, CCBC Gets Biologics License
We have released coverage of this week’s stem cell industry activity that I am excited to share with you. It was a major week for stem cells, with CDI launching Opsis Therapeutics, Provia Laboratories expanding its stem cell product portfolio, CCBC getting a FDA Biologics License for CLEVECORD™, STEMCELL Technologies exploring genomic instability in an upcoming webinar, and iPSCs turning 10. [Read more…]
FDA Approves the Cleveland Cord Blood Center’s CLEVECORD™ for Stem Cell Transplants
CLEVELAND, Sept. 12, 2016 /PRNewswire-USNewswire/ — The U.S. Food and Drug Administration (FDA) has issued a biologics license to the Cleveland Cord Blood Center (CCBC) for CLEVECORD™, a stem cell product (HPC, Cord Blood) derived from umbilical cord blood. Under this license, CCBC is authorized to manufacture CLEVECORD, for use in unrelated hematopoietic cell transplantation in patients with disorders affecting the hematopoietic system such as leukemia, lymphoma and immune system disorders.
“Obtaining FDA licensure for CLEVECORD is reflective of the Cleveland Cord Blood Center’s dedication to meeting the highest quality standards in the industry for distribution of our cord blood products to transplant centers throughout the U.S. and around the world,” said Wouter Van’t Hof, the CCBC’s Cord Blood Bank Director. “The ability to meet such standards is indicative of the commitment of our organization to providing high quality transplant options to patient populations that are underserved in hematopoietic transplantation. It also stages the pursuit of new life-saving and life-enhancing research and product development opportunities.”
Key Benefits of Public vs. Private Cord Blood Banking
The cord blood banking industry first emerged in the early 1990’s with the formation of three private cord blood banks within the United States, Cord Blood Registry, Cryo-Cell, and Viacord, all of which are AABB accredited banks.
Benefits of Cord Blood Banking | Public and Private
In this article:
- Cord Blood Banking Companies
- Key Benefits of Public Cord Blood Donation
- Key Benefits of Private Cord Blood Storage
Cord Blood Banking Companies
Over the past twenty years, cord blood banks have since become common across North America, South America, Europe, Asia, and the Middle East.
Today, a major variable within the cord blood banking industry is the divide between private and public cord blood banking. [Read more…]
Cesca Therapeutics Granted Two Patents for Rapid Infusion of Autologous Bone Marrow Derived Stem Cells
Technology Fundamental to Cesca’s Proprietary SurgWerks™ Platform for CLI and AMI
RANCHO CORDOVA, Calif., Sept. 19, 2016 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the United States Patent & Trademark Office (USPTO) has granted the Company the first two of a family of patent applications related to Cesca’s proprietary methods for the treatment of ischemic cardiovascular disorders, such as critical limb ischemia (CLI) and acute myocardial infarction (AMI). [Read more…]
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 32
- Next Page »